News

Strategic Partnership Established between JECHO and Sartorius

JECHO Biopharmaceuticals Co., Ltd. and Sartorius Stedim Biotech China under Sartorius Group announced that, the two parties formally signed the agreement on the development of upstream technique for cell culture, and formed a close strategic cooperation partnership. On September 21, 2017, both parties held the signing ceremony in Hilton Hotel, Sino-Singapore Tianjin Eco-City.




 

In this technical cooperation, both parties will carry out comprehensive technical cooperation of the cell culture process in the field of gene therapy. The breakthrough of large-scale cell serum-free suspension culture technique is the key of new-type targeting gene drug and recombinant vaccine production technique therapy. In the cooperation, a comprehensive process research will be carried out by utilizing the automatic high-throughput cell culture platform and on-line monitoring technology, to expect major technical breakthrough in this field, and thus accelerate the R&D and production capacity of tumor targeting drug in China.
 

"As the partner of pharmaceutical enterprises and the leader of upstream technique industry, Sartorius strongly supports the rapid development of China's biopharmaceutical industry from the four aspects: the acceleration of clinic progress, improvement of protein expression, quality sourced by design and stable production." Dr. Joerg Lindenblatt, the Senior Vice President of Sartorius in Asia Pacific said that, "As JECHO and Sartorius hold the same idea on innovation and quality, the technical cooperation between both parties will turn a new chapter for the targeted therapy for brain tumors, and the drug quality will also be comparable to European and American international standard. Meanwhile, Sartorius will provide full support for the construction of the platform of JECHO's North American R&D department and the technical transfer between China and America, and address the latest techniques to China faster. We believe this cooperation will lay solid foundation for the long-term sustainable development between both parties, and promote the development of China's medical business with high-efficiency innovative drugs."

 

"As the new power of innovative drug development, JECHO is devoted to the development of anti-tumor and anti-infection biological drugs in high quality, and is constructing multiple pilot scale test and large-scale biological medicine production lines. It is anticipated that the future R&D and production will cover multiple biological drugs for brain cancer and so on, achieving excellent social benefits for the medical business." Dr. Zhu Jianwei, the CEO and Chief Scientist of JECHO said that, "This technical cooperation with Sartorius will contribute to introducing innovative research ideas and world-leading technology platforms, and accelerating the development of biological drugs for targeted immunotherapy, so as to pave the way to product innovative drugs."


In this technical cooperation, Sartorius will provide JECHO with a cell culture platform covering R&D, pilot test and commercial production, and provide strong technical support with the rich experience in cooperating with global pharmaceutical companies. With the leading position in process innovation, this technical cooperation will certainly contribute to a boom of China's precision medicine.

 

About JECHO 

JECHO is constructing the bio-pharmaceutical R&D and production base in world-leading level. It focuses on the R&D of innovative biological drugs for treating the major human diseases. (www.jechobio.com

 

About Sartorius Stedim

Sartorius Stedim is a world-leading equipment and service provider in bio-pharmaceutical industry, providing safe, timely, economical integrated solutions for the global bio-pharmaceutical development and production. (www.sartorius.com.cn

© Jecho Biopharmaceuticals 2019-2021

2633 Zhongbin Avenue, China-Singapore Tianjin Eco-City, Binhai New Area, Tianjin 300467, P.R.C.